Phio Pharmaceuticals To Present New Data on PD-1 Targeting INTASYL at the 2021 American Association for Cancer Research (AACR) Annual Meeting
Phio Pharmaceuticals Corp. announced new study data on its product candidate, PH-762, which targets PD-1 and shows promise in tumor control. This presentation will be part of the AACR Annual Meeting 2021, held virtually from April 10-15 and May 17-21. The poster titled "Intratumoral INTASYL™ self-delivering RNAi targeting PD-1" will explore the treatment's effects similar to systemic anti-PD-1 antibodies. Further details will be available on the Company’s website after the presentation.
- None.
- None.
MARLBOROUGH, Mass., March 11, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced it will present new study data regarding the direct drug application of its product candidate, PH-762, at the AACR Annual Meeting 2021. The AACR 2021 meeting will be held in a virtual format over two weeks, April 10-15 and May 17-21.
Logo - https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
Presentation details:
Title: | Intratumoral INTASYL™ self-delivering RNAi targeting PD-1 provides in vivo tumor control and mechanistic modulation of tumor microenvironment analogous to that of systemic anti-PD-1 antibody |
Authors: | Benjamin Cuiffo, et al. |
Session Title: | Immunomodulatory Agents and Interventions |
Abstract Number: | 1739 |
The poster presentation will be made available on the "Investors – Events and Presentations" section of the Company's website.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. These statements are based only on our current beliefs, expectations and assumptions regarding the impact to our business and operations by the recent coronavirus outbreak, results from our preclinical and clinical activities, the development of our product candidates, the ability to obtain future financing, the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
Contact Phio Pharmaceuticals Corp.
ir@phiopharma.com
Investor Contact
Ashley R. Robinson
LifeSci Advisors
arr@lifesciadvisors.com
View original content:http://www.prnewswire.com/news-releases/phio-pharmaceuticals-to-present-new-data-on-pd-1-targeting-intasyl-at-the-2021-american-association-for-cancer-research-aacr-annual-meeting-301245148.html
SOURCE Phio Pharmaceuticals Corp.
FAQ
What is the significance of PH-762 presented by Phio Pharmaceuticals at AACR 2021?
When will Phio Pharmaceuticals present study data at the AACR Annual Meeting 2021?
Where can I find more information about Phio Pharmaceuticals' presentation on PH-762?
What type of therapeutic platform does Phio Pharmaceuticals use?
What is the abstract number for Phio Pharmaceuticals' study on PH-762?
